INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nasdaq: INVO) on March 28, 2023, reporting events occurring on March 23, 2023. The filing details the entry into a Material Definitive Agreement for a registered direct offering and a concurrent private placement of equity securities.
Key Financial Metrics and Capital Structure
- Gross Proceeds Raised: Approximately $3.0 million (closed March 27, 2023).
- Potential Additional Proceeds: Approximately $3.5 million if all Private Placement Warrants are exercised for cash.
- Securities Issued:
- 1,380,000 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 2,300,000 shares (exercise price $0.01).
- Private Placement Warrants to purchase up to 5,520,000 shares (exercise price $0.63).
- Placement Agent Compensation: 5.0% of gross proceeds plus warrants to purchase 147,200 shares (exercise price $0.8965).
- Debt Repayment Obligation: The Company may use proceeds to repay $500,000 in convertible debentures issued in February 2023 at 105% of principal ($525,000) if requested by investors.
Material Changes and Use of Proceeds
The primary material change is the capital raise and the associated dilution from new shares and warrants. The Company intends to use the net proceeds for the following purposes:
- Repayment of outstanding convertible debentures (up to $525,000).
- Payment of the down payment for the acquisition of the Wisconsin Facility Institute.
- Working capital, capital expenditures, and general corporate purposes.
Guidance, Risks, and Restrictions
Management Commentary and Restrictions:
- Lock-Up Agreements: Officers and directors are restricted from selling or hedging common stock for 180 days from the offering date.
- Issuance Restrictions: The Company is prohibited from issuing new common stock or equivalents for 45 days post-closing (subject to exceptions) and is barred from variable rate transactions for one year.
- Registration Obligations: The Company must file a Form S-1 resale registration statement within 30 days of closing and use commercially reasonable efforts to make it effective within 75 days.
Risks and Contingencies:
- The filing includes standard forward-looking statement disclaimers regarding the ability to maintain Nasdaq listing and the success of the Wisconsin Facility Institute acquisition.
- Actual results may differ materially from expectations due to risks inherent in the biotechnology sector and capital markets.
Investor Verification Checklist
- Verify the final closing date and exact net proceeds after deducting placement agent fees and offering expenses.
- Confirm whether the $500,000 convertible debentures were repaid using the offering proceeds.
- Monitor the status of the Form S-1 resale registration statement required within 30 days of the March 27, 2023 closing.
- Review the terms of the acquisition of the Wisconsin Facility Institute to assess the use of the down payment.
- Check subsequent filings for any updates on the exercise of Pre-Funded Warrants or Private Placement Warrants.